IRE-1α inhibitors

A compound or pharmaceutically acceptable salt thereof, where the compound is represented by structural formula (A-3):

• wherein:
• R3 and R4 independently are hydrogen;
• alkyl or alkoxy, each optionally substituted with (1) a C1-C6 hydrocarbon chain containing an N or O atom, or (2) a cycloalkyl which optionally contains 1 or 2 heteroatoms selected from N, O, and S;
• R6 is alkynyl or phenyl, each optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkyl, alkoxy, and
• a 5- or 6-membered heteroaryl that is substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkyl, alkoxy, and
• wherein n1 is 0, 1, or 2;
• R7 is H or methyl;
• R9 and R10 are independently hydrogen;
• alkyl;
• alkoxylalkyl;
• or
• wherein n2 is 0, 1, 2, or 3;
• or,
• R9 and R10, together with the nitrogen atom to which they are attached, form a heterocycle containing 1, 2, or 3 heteroatoms selected from N, O, and S, optionally substituted with 1, 2, or 3 substituents selected independently from R11;
• R11 is hydrogen or alkyl;
• R12 is amino;
• alkoxy;
• or a 5- or 6-membered heterocycle having 1, 2, or 3 heteroatoms selected from N, O, and S and optionally substituted with 1, 2, or 3 substituents selected independently from R11;
• with the exception of compounds of structural formula (A-3) in which:
• R3 and R4 are hydrogen and R6 is optionally substituted phenyl.